Chinese AI drug researcher XtalPi expects to turn first annual profit on 193% revenue jump
Shenzhen-based company projects net profit of at least US$14.5 million in 2025 on narrowing losses in core businesses, investment gains
Chinese artificial intelligence-powered drug researcher XtalPi Holdings said it expects to turn its first annual profit on the back of strong revenue growth, according to a corporate filing.
The Shenzhen-based company projected a swing to a net profit of at least 100 million yuan (US$14.5 million) in 2025 from a net loss of around 1.5 billion yuan in 2024, notching its first full-year profit, according to a filing with the Hong Kong stock exchange on Tuesday.
XtalPi attributed the earnings boost to “a substantial increase” in revenue, which came to at least 780 million yuan for the year ended December, the filing said.
This represented a nearly 193 per cent jump from a year earlier, according to the company, which cited narrowing losses in its core intelligent robotics and drug discovery operations.
XtalPi’s profit was also helped by a sharp rise in gains on financial assets, expected to exceed 500 million yuan, the filing said.
XtalPi’s share lost 2 per cent to HK$9.54 on Tuesday, before it released the alert.